Logo image of NGNE

NEUROGENE INC (NGNE) Stock Fundamental Analysis

NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD

20.09  +0.34 (+1.72%)

After market: 20.23 +0.14 (+0.7%)

Fundamental Rating

2

Taking everything into account, NGNE scores 2 out of 10 in our fundamental rating. NGNE was compared to 555 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NGNE has reported negative net income.
In the past year NGNE has reported a negative cash flow from operations.
NGNE had negative earnings in each of the past 5 years.
In the past 5 years NGNE always reported negative operating cash flow.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -22.38%, NGNE is in the better half of the industry, outperforming 76.58% of the companies in the same industry.
Looking at the Return On Equity, with a value of -24.21%, NGNE belongs to the top of the industry, outperforming 82.16% of the companies in the same industry.
Industry RankSector Rank
ROA -22.38%
ROE -24.21%
ROIC N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NGNE has more shares outstanding than it did 1 year ago.
NGNE has more shares outstanding than it did 5 years ago.
NGNE has a better debt/assets ratio than last year.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.95 indicates that NGNE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.95, NGNE is in the better half of the industry, outperforming 78.74% of the companies in the same industry.
NGNE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
NGNE has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.95
ROIC/WACCN/A
WACC8.99%
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

NGNE has a Current Ratio of 20.84. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
NGNE's Current ratio of 20.84 is amongst the best of the industry. NGNE outperforms 93.87% of its industry peers.
NGNE has a Quick Ratio of 20.84. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
NGNE's Quick ratio of 20.84 is amongst the best of the industry. NGNE outperforms 93.87% of its industry peers.
Industry RankSector Rank
Current Ratio 20.84
Quick Ratio 20.84
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

NGNE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.24%.
EPS 1Y (TTM)-51.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -8.76% on average over the next years.
The Revenue is expected to grow by 114.00% on average over the next years. This is a very strong growth
EPS Next Y-14.52%
EPS Next 2Y-9.89%
EPS Next 3Y-8.76%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y114%

3.3 Evolution

NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2029 2030 2031 2032 100M 200M 300M 400M 500M
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NGNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as NGNE's earnings are expected to decrease with -8.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.89%
EPS Next 3Y-8.76%

More info and screens

0

5. Dividend

5.1 Amount

NGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROGENE INC

NASDAQ:NGNE (7/3/2025, 7:53:53 PM)

After market: 20.23 +0.14 (+0.7%)

20.09

+0.34 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners116.08%
Inst Owner Change9.1%
Ins Owners9.23%
Ins Owner Change3.47%
Market Cap286.48M
Analysts84.62
Price Target43.45 (116.28%)
Short Float %17.34%
Short Ratio10.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.3%
Min EPS beat(2)4.5%
Max EPS beat(2)14.11%
EPS beat(4)3
Avg EPS beat(4)7.61%
Min EPS beat(4)-1.77%
Max EPS beat(4)14.11%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.05%
PT rev (3m)-19.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.31%
EPS NY rev (1m)-0.75%
EPS NY rev (3m)-10.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 309.71
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-4.35
EYN/A
EPS(NY)-5.16
Fwd EYN/A
FCF(TTM)-5.01
FCFYN/A
OCF(TTM)-4.95
OCFYN/A
SpS0.06
BVpS21.77
TBVpS21.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.38%
ROE -24.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.29%
Cap/Sales 87.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.84
Quick Ratio 20.84
Altman-Z 5.95
F-Score5
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)35.41%
Cap/Depr(5y)127.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
EPS Next Y-14.52%
EPS Next 2Y-9.89%
EPS Next 3Y-8.76%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y114%
EBIT growth 1Y-58.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.3%
OCF growth 3YN/A
OCF growth 5YN/A